wuhan easy diagnosis biomedicine (002932.SZ) released its performance for the first three quarters, with a net income of 80.9384 million yuan, a year-on-year decrease of 44.30%.

Zhitong Finance · Oct 30 19:57

Wuhan Easy Diagnosis Biomedicine (002932.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...

According to the Zhitong Caijing APP, Wuhan Easy Diagnosis Biomedicine (002932.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue of 0.226 billion yuan, a year-on-year decrease of 63.95%. Net income attributable to shareholders of the listed company was 80.9384 million yuan, a year-on-year decrease of 44.30%. Net loss after deducting non-recurring gains and losses attributable to shareholders of the listed company was 39.0766 million yuan.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

明德生物(002932.SZ)发布前三季度业绩，净利润8093.84万元，同比下降44.30%

wuhan easy diagnosis biomedicine (002932.SZ) released its performance for the first three quarters, with a net income of 80.9384 million yuan, a year-on-year decrease of 44.30%.

Risk Disclaimer

Statement